416 related articles for article (PubMed ID: 26294211)
1. Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.
Hurley PJ; Hughes RM; Simons BW; Huang J; Miller RM; Shinder B; Haffner MC; Esopi D; Kimura Y; Jabbari J; Ross AE; Erho N; Vergara IA; Faraj SF; Davicioni E; Netto GJ; Yegnasubramanian S; An SS; Schaeffer EM
Cancer Res; 2015 Oct; 75(20):4322-34. PubMed ID: 26294211
[TBL] [Abstract][Full Text] [Related]
2. Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome.
Hurley PJ; Marchionni L; Simons BW; Ross AE; Peskoe SB; Miller RM; Erho N; Vergara IA; Ghadessi M; Huang Z; Gurel B; Park BH; Davicioni E; Jenkins RB; Platz EA; Berman DM; Schaeffer EM
Proc Natl Acad Sci U S A; 2012 Sep; 109(37):14977-82. PubMed ID: 22927397
[TBL] [Abstract][Full Text] [Related]
3. SPARCL1 suppresses metastasis in prostate cancer.
Xiang Y; Qiu Q; Jiang M; Jin R; Lehmann BD; Strand DW; Jovanovic B; DeGraff DJ; Zheng Y; Yousif DA; Simmons CQ; Case TC; Yi J; Cates JM; Virostko J; He X; Jin X; Hayward SW; Matusik RJ; George AL; Yi Y
Mol Oncol; 2013 Dec; 7(6):1019-30. PubMed ID: 23916135
[TBL] [Abstract][Full Text] [Related]
4. Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers.
Hu H; Zhang H; Ge W; Liu X; Loera S; Chu P; Chen H; Peng J; Zhou L; Yu S; Yuan Y; Zhang S; Lai L; Yen Y; Zheng S
Clin Cancer Res; 2012 Oct; 18(19):5438-48. PubMed ID: 22891198
[TBL] [Abstract][Full Text] [Related]
5. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
Axlund SD; Lambert JR; Nordeen SK
Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
[TBL] [Abstract][Full Text] [Related]
6. SPARCL1 Is a Novel Prognostic Biomarker and Correlates with Tumor Microenvironment in Colorectal Cancer.
Zhang HP; Wu J; Liu ZF; Gao JW; Li SY
Biomed Res Int; 2022; 2022():1398268. PubMed ID: 35111844
[TBL] [Abstract][Full Text] [Related]
7. SPARCL1 a novel player in cancer biology.
Gagliardi F; Narayanan A; Mortini P
Crit Rev Oncol Hematol; 2017 Jan; 109():63-68. PubMed ID: 28010899
[TBL] [Abstract][Full Text] [Related]
8. Androgen action during prostate carcinogenesis.
Wang D; Tindall DJ
Methods Mol Biol; 2011; 776():25-44. PubMed ID: 21796518
[TBL] [Abstract][Full Text] [Related]
9. Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progression.
Godoy AS; Sotomayor PC; Villagran M; Yacoub R; Montecinos VP; McNerney EM; Moser M; Foster BA; Onate SA
Biochem Biophys Res Commun; 2012 Jul; 423(3):564-70. PubMed ID: 22695118
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
12. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
Chung LW; Baseman A; Assikis V; Zhau HE
J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
[TBL] [Abstract][Full Text] [Related]
13. Enhanced SPARCL1 expression in cancer stem cells improves preclinical modeling of glioblastoma by promoting both tumor infiltration and angiogenesis.
Gagliardi F; Narayanan A; Gallotti AL; Pieri V; Mazzoleni S; Cominelli M; Rezzola S; Corsini M; Brugnara G; Altabella L; Politi LS; Bacigaluppi M; Falini A; Castellano A; Ronca R; Poliani PL; Mortini P; Galli R
Neurobiol Dis; 2020 Feb; 134():104705. PubMed ID: 31830525
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
[TBL] [Abstract][Full Text] [Related]
15. Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome.
Leach DA; Need EF; Toivanen R; Trotta AP; Palethorpe HM; Tamblyn DJ; Kopsaftis T; England GM; Smith E; Drew PA; Pinnock CB; Lee P; Holst J; Risbridger GP; Chopra S; DeFranco DB; Taylor RA; Buchanan G
Oncotarget; 2015 Jun; 6(18):16135-50. PubMed ID: 25965833
[TBL] [Abstract][Full Text] [Related]
16. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 is a potent inducer of S100P, which is up-regulated in androgen-refractory and metastatic prostate cancer.
Hammacher A; Thompson EW; Williams ED
Int J Biochem Cell Biol; 2005 Feb; 37(2):442-50. PubMed ID: 15474988
[TBL] [Abstract][Full Text] [Related]
18. SPARCL1 is a novel predictor of tumor recurrence and survival in hilar cholangiocarcinoma.
Yu Y; Chen Y; Ma J; Yu X; Yu G; Li Z
Tumour Biol; 2016 Mar; 37(3):4159-67. PubMed ID: 26490986
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor regulates CD168 expression and signaling in prostate cancer.
Lin SL; Chang D; Chiang A; Ying SY
Carcinogenesis; 2008 Feb; 29(2):282-90. PubMed ID: 18174258
[TBL] [Abstract][Full Text] [Related]
20. The KDM6A-SPARCL1 axis blocks metastasis and regulates the tumour microenvironment of gastrointestinal stromal tumours by inhibiting the nuclear translocation of p65.
Shen C; Han L; Liu B; Zhang G; Cai Z; Yin X; Yin Y; Chen Z; Zhang B
Br J Cancer; 2022 Jun; 126(10):1457-1469. PubMed ID: 35136209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
